PURPOSE: The prognosis for children with IPAH unresponsive to therapy is poor. We investigated the plasma proteome for a molecular basis of good versus poor outcome to long-term vasodilator therapy. EXPERIMENTAL DESIGN: Plasma was collected at baseline or shortly after therapy initiation and following chronic vasodilator therapy, then divided into those with good outcome (n = 8), and those with a poor outcome (n = 7). To identify proteins unique to either outcome, we used differential gel electrophoresis and mass spectrometry. Results were confirmed by commercial enzyme-linked immunosorbent assay. RESULTS: Before and after therapy, SAA-4 was 4-fold lower in those with good outcome compared to those with poor outcome, while serum paraoxonase/arylesterase-1 was increased 2-fold in those with good outcome versus poor outcome. After therapy, haptoglobin and hemopexin were 1.45- and 1.8-fold lower, respectively, in those with a good versus poor outcome. Among those with a good outcome, SAP was 1.3-fold lower prior to therapy. CONCLUSIONS AND CLINICAL RELEVANCE: SAP and SAA-4 regulate circulating mononuclear phagocytes. As such, they may contribute to the differential response to chronic vasodilator therapy in the context of inflammation in IPAH.
PURPOSE: The prognosis for children with IPAH unresponsive to therapy is poor. We investigated the plasma proteome for a molecular basis of good versus poor outcome to long-term vasodilator therapy. EXPERIMENTAL DESIGN: Plasma was collected at baseline or shortly after therapy initiation and following chronic vasodilator therapy, then divided into those with good outcome (n = 8), and those with a poor outcome (n = 7). To identify proteins unique to either outcome, we used differential gel electrophoresis and mass spectrometry. Results were confirmed by commercial enzyme-linked immunosorbent assay. RESULTS: Before and after therapy, SAA-4 was 4-fold lower in those with good outcome compared to those with poor outcome, while serum paraoxonase/arylesterase-1 was increased 2-fold in those with good outcome versus poor outcome. After therapy, haptoglobin and hemopexin were 1.45- and 1.8-fold lower, respectively, in those with a good versus poor outcome. Among those with a good outcome, SAP was 1.3-fold lower prior to therapy. CONCLUSIONS AND CLINICAL RELEVANCE: SAP and SAA-4 regulate circulating mononuclear phagocytes. As such, they may contribute to the differential response to chronic vasodilator therapy in the context of inflammation in IPAH.
Authors: Peter Schott; Silke S Singer; Harald Kögler; Daniel Neddermeier; Kirsten Leineweber; Otto-Erich Brodde; Vera Regitz-Zagrosek; Bernhard Schmidt; Hassan Dihazi; Gerd Hasenfuss Journal: Proteomics Date: 2005-04 Impact factor: 3.984
Authors: Paul Jan Willem Herman Kappelle; Johan Bijzet; Bouke Pier Hazenberg; Robin Pieter Frank Dullaart Journal: Arch Med Res Date: 2011-04 Impact factor: 2.235
Authors: M E Yeager; C M Nguyen; D D Belchenko; K L Colvin; S Takatsuki; D D Ivy; K R Stenmark Journal: Eur Respir J Date: 2011-06-23 Impact factor: 16.671
Authors: Vanesa A Karamanian; Michael Harhay; Gregory R Grant; Harold I Palevsky; William E Grizzle; Roham T Zamanian; Kaori Ihida-Stansbury; Darren B Taichman; Steven M Kawut; Peter L Jones Journal: Pulm Circ Date: 2014-06 Impact factor: 3.017
Authors: Ian Adatia; Sheila G Haworth; Max Wegner; Robyn J Barst; Dunbar Ivy; Kurt R Stenmark; Abraham Karkowsky; Erika Rosenzweig; Christopher Aguilar Journal: Pulm Circ Date: 2013-01 Impact factor: 3.017
Authors: Kelley L Colvin; Melanie J Dufva; Ryan P Delaney; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager Journal: Front Pediatr Date: 2014-02-03 Impact factor: 3.418